Key result
Aldosterone antagonists significantly reduced the risk of sudden cardiac death by 19% (RR 0.81) compared with placebo or standard medication in patients with heart failure and/or post-myocardial infarction.
Why the study?
Do aldosterone antagonists reduce sudden cardiac death and mortality in patients with heart failure or post-myocardial infarction?
Meta-Analysis (n=19,333)
Yes
Do aldosterone antagonists reduce sudden cardiac death and mortality in patients with heart failure or post-myocardial infarction?
Effect estimate: RR 0.81 (95% CI 0.71-0.92)
Absolute Event Rate: 4.88% vs 6.08%
p-value: p=0.002
Aldosterone antagonists significantly reduce the risk of sudden cardiac death, all-cause mortality, and cardiovascular mortality in patients with heart failure or post-myocardial infarction, though they increase the risk of hyperkalemia, renal dysfunction, and gynecomastia.
No takes yet. Share an insight, caveat, or question.
Reinforces aldosterone antagonists as standard to reduce sudden cardiac death in heart failure or post-MI; confirms mortality benefits across randomized trials.
Le et al. (2016) conducted a meta-analysis in Heart Failure and Post-Myocardial Infarction (n=19,333). Aldosterone Antagonists (spironolactone, eplerenone, canrenoate potassium) vs. Placebo or standard treatment was evaluated on Sudden cardiac death (SCD) (RR 0.81, 95% CI 0.71-0.92, p=0.002). Aldosterone antagonists significantly reduced the risk of sudden cardiac death by 19% (RR 0.81) compared with placebo or standard medication in patients with heart failure and/or post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: